AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
TLC G-65, a new drug for the most common systemic bacterial infection afflicting AIDS patients, Mycobacterium avium-intracellulare (MAI), has entered a Phase III clinical trial in Europe, the Liposome Company Inc., Princeton, New Jersey, announced.
The MAI study was initiated at St. Stephen's Hospital, London, England, one of the most prestigious AIDS therapy centers in the United Kingdom. It is led by principal investigator Dr. Brian Gazzard. At least one additional study location will be added shortly.
TLC G-65, a proprietary drug of the Liposome Company, is a liposomal aminoglycoside antibiotic that has previously been shown in …